Meribel Pharma Solutions Launches
A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions, has launched today with an extensive integrated network across Europe.
The firm has ten manufacturing sites and three drug development services sites, situated across France, Spain and Sweden, following the acquisition of the CDMO Synerlab Group and seven European manufacturing facilities from Recipharm last year.
Meribel Pharma Solutions is headed up by an experienced team including CEO, Bruce Vielle, formerly President, CEO of Synerlab, and COO, Steve Leonard, who joins the firm from Integra Life Sciences where he was Corporate VP, Global Operations & Supply Chain. Prior to that, he was SVP, Head of Global Operations at Catalent.
Meribel Pharma Solutions specializes in oral solid dose (OSD) manufacturing, semi-solid dosage formulations, and sterile drug products. They have centers of excellence in drug development, lyophilisation, preservative-free multidose technologies, and flexible stick-pack and sachet production. The company offers technical expertise from concept to commercialization, supporting both human and veterinary health products under strict global regulatory certifications.
Meribel Pharma Solutions CEO, Bruce Vielle said: “There is a gap in the market for a niche-player, mid-sized CDMO that’s focused, agile, and dedicated to solving complex challenges, and we are well positioned to fulfill this unmet need.
“We have invested heavily in the latest technologies and expanded our capacity to meet the evolving needs of our customers. As a unified organisation, our foundations are built on quality and reliability. We bring together greater resources, deeper expertise, and enhanced agility, enabling us to meet our customers' requirements better than ever before."
The name Meribel Pharma Solutions is inspired by the Meribel mountain range in the Alps. Located in the Three Valleys in France, the name symbolises the firm bringing together manufacturing excellence from across three countries, France, Spain and Sweden. It is also a nod to the firm’s commitment to helping customers navigate complex challenges and reach new heights in drug development and manufacturing.
